Pillstats
Rx only · Injection, Solution · Subcutaneous

Benralizumab

Brands: Fasenra · Benralizumab

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US3 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCR03DX10
RxCUI (US)1989100
US makers1 labelers
Packages6
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

5.2K10K16K21K2025 Q12025 Q22025 Q32025 Q42026 Q1
17K
Rx · 2026 Q1
16K
Units dispensed
+3%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
AstraZeneca Pharmaceuticals LPunknown6SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Oct 8, 2025
    RECALLRecall (Class II): Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca A…

    Lack of Assurance of Sterility: — Recalling firm: ASTRAZENECA PHARMACEUTICALS — Nationwide in the U.S